Cytek Biosciences reports Q2 EPS (4c), consensus (1c)

Reports Q2 revenue $45.6M, consensus $46.35M. “The progress we achieved in the first half of this year is underscored by steady growth in our FSP unit placements, and in our recurring revenue businesses, despite a macro environment that remains challenging. I am also proud of our team’s continued focus on innovation and the launch of the Cytek Aurora Evo system, which we believe will accelerate broader adoption of our solutions,” said Wenbin Jiang, CEO of Cytek Biosciences (CTKB).